TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32709235

Group type: EXPERIMENTAL
Intervention: Pre- and post-bronchodilator spirometry tests
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Adapted American Thoracic Society Epidemiological Questionnaire
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Air quality measures assessment (particulate matter, carbon monoxide, carbon dioxide, humidity)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Health care utilization data from electronic medical records
Number of subjects: 220
Study: 32709249

Group type: EXPERIMENTAL
Intervention: Individualized quality improvement based on the Computer Analysing system (CASE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pre-intervention stage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-intervention stage (with education)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-intervention stage (without education)
Number of subjects: 30
Study: 32709381

Group type: EXPERIMENTAL
Intervention: Uterine transplantation
Number of subjects: 9
Study: 32709653

Group type: EXPERIMENTAL
Intervention: Systematic analysis of selected plasma and transcriptomic biomarkers (procalcitonin, IL-6, IL-10, IP10) at delivery and every other week for occurrence of sepsis.
Number of subjects: 580
Study: 32710011

Group type: EXPERIMENTAL
Intervention: Antibody-radionuclide conjugate targeting CD45
Number of subjects: 0
Study: 32710245

Group type: EXPERIMENTAL
Intervention: 2-dose HAB 720
Number of subjects: 1
Study: 32710657

Group type: EXPERIMENTAL
Intervention: Nutrition education for families of infants
Number of subjects: 14241
Study: 32710922

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study: 32711035

Group type: EXPERIMENTAL
Intervention: Liver stiffness (LS) assessment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Liver stiffness (LS) of abstinent subjects
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: CAP™ values
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Systematic median-term follow-up
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Liver stiffness (LS)
Number of subjects: 129
Study: 32711479

Group type: EXPERIMENTAL
Intervention: Elderly CKD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group with normal kidney function (estimated glomerular filtration rate ≥ 60 ml/min/1.73m²)
Number of subjects: 0
Study: 32711502

Group type: EXPERIMENTAL
Intervention: Adjustable single 8-0 polypropylene suture for scleral fixation without conjunctival dissection
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 27
Study: 32711542

Group type: EXPERIMENTAL
Intervention: CT-guided radioactive RIS implantation
Number of subjects: 66
Study: 32711544

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs as biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in miRNA during surveillance
Number of subjects: 0
Study: 32711747

Group type: EXPERIMENTAL
Intervention: High oxygen exposure (≥33.1% oxygen)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Intermediate oxygen exposure (29.1%-33.1% oxygen)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: High/intermediate oxygen exposure
Number of subjects: 704

Group type: COMPARATOR
Intervention: Low oxygen exposure (below both cutoffs)
Number of subjects: 704
Study: 32711950

Group type: EXPERIMENTAL
Intervention: Surgery (major elective abdominal surgery)
Number of subjects: 15
Study: 32712225

Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 20
Study: 32712650

Group type: EXPERIMENTAL
Intervention: PD-L1(+)-CTCs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Triple negative (TN) phenotype
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Number of metastatic treatments
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: >2 metastatic sites
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ≥5 CTCs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Progesterone receptor negativity
Number of subjects: 72

Group type: COMPARATOR
Intervention: TN phenotype and >2 metastatic sites
Number of subjects: 72
Study: 32712658

Group type: EXPERIMENTAL
Intervention: CIR-Ala
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: CIR-Ala, CIR-Gly, CIR-Ile, smoking, leisure physical activity, and body weight
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Biomarker-estimated AS intake
Number of subjects: 145
Study: 32712702

Group type: EXPERIMENTAL
Intervention: FDG PET/CT performed from day 6 to day 14 of the onset of symptoms
Number of subjects: 13
Study: 32712806

Group type: EXPERIMENTAL
Intervention: Single-agent belantamab mafodotin (2.5 mg/kg)
Number of subjects: 95
Study: 32712962

Group type: EXPERIMENTAL
Intervention: Different surgical techniques for removal of mandibular wisdom teeth
Number of subjects: 4643

Group type: COMPARATOR
Intervention: Lingual retractor vs no lingual retractor
Number of subjects: 4643

Group type: COMPARATOR
Intervention: Lingual split with chisel vs surgical hand-piece for bone removal
Number of subjects: 4643

Group type: COMPARATOR
Intervention: Mechanical vs manual irrigation method
Number of subjects: 4643

Group type: COMPARATOR
Intervention: High vs low irrigation volume
Number of subjects: 4643

Group type: COMPARATOR
Intervention: Low vs high irrigation volume
Number of subjects: 4643

Group type: COMPARATOR
Intervention: Primary vs secondary wound closure
Number of subjects: 4643

Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP) or platelet rich fibrin (PRF) in sockets
Number of subjects: 4643
Study: 32713940

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 11
Study: 32714156

Group type: EXPERIMENTAL
Intervention: Long-term spinal cord stimulation
Number of subjects: 0
Study: 32714178

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial Direct Current Stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32714280

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32714408

Group type: EXPERIMENTAL
Intervention: Compound Danshen dripping pills (CDDP)
Number of subjects: 0
Study: 32714423

Group type: EXPERIMENTAL
Intervention: Baduanjin sequential therapy (BST) for 24 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 96
Study: 32714561

Group type: EXPERIMENTAL
Intervention: Engagement intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 32715151

Group type: EXPERIMENTAL
Intervention: Attendance to a course on SNS use (T1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle education and brain functioning (C1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive control group (waiting list) (C)
Number of subjects: 0
Study: 32715396

Group type: EXPERIMENTAL
Intervention: aMCI APOEε4 carriers
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 75
Study: 32715736

Group type: EXPERIMENTAL
Intervention: erenumab 70 mg s.c. (every 28 days) for a total of three administrations
Number of subjects: 40
Study: 32715796

Group type: EXPERIMENTAL
Intervention: Auto-titrating continuous positive airway pressure (PAP) therapy initiated in 13 subjects who screened positive for OSA.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Screening using sleep apnea clinical score (SAC) and portable sleep testing.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Screening for OSA with a portable sleep testing system.
Number of subjects: 31
Study: 32715844

Group type: EXPERIMENTAL
Intervention: Prespecified risk criteria from FAST-TAVI for early discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: In-hospital complications before discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Post-discharge complications
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Overall mortality within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Cardiac rehospitalization within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Any stroke within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Vascular-access-related complications within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Life-threatening bleeding within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Kidney failure within 1 year after discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for low risk and early discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for high risk and late discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for low risk but late discharge
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for high risk but early discharge
Number of subjects: 502
Study: 32715853

Group type: EXPERIMENTAL
Intervention: DFMO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study: 32716060

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Yinchenghao decoction (YCHD)
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Danxioling and Yiganling
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Salvia
Number of subjects: 2007
Study: 32716292

Group type: EXPERIMENTAL
Intervention: Higher-dose tigecycline (100 mg q12h) in CRRT group (7 cases)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Higher-dose tigecycline (100 mg q12h) in non-CRRT group (9 cases)
Number of subjects: 16
Study: 32716355

Group type: EXPERIMENTAL
Intervention: Combination of MTA and PA visual rating scales
Number of subjects: 73

Group type: COMPARATOR
Intervention: Single visual rating scale
Number of subjects: 73

Group type: COMPARATOR
Intervention: Gray matter volumetric measures
Number of subjects: 73
Study: 32716707

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 208757

Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 208757

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 208757

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 208757

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 208757
Study: 32716739

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 104
Study: 32716740

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks until hCG normalization, followed by 3 consolidation cycles
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 15

Group type: COMPARATOR
Intervention: Actinomycin D or combination chemotherapy/surgery
Number of subjects: 15
Study: 32716957

Group type: EXPERIMENTAL
Intervention: Standardized diagnostic tool (Kiddie-SADS Present and Lifetime psychosis section)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Standardized assessment
Number of subjects: 302
Study: 32717265

Group type: EXPERIMENTAL
Intervention: Actigraphy-estimated sleep fragmentation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Actigraphy-estimated total sleep time and interdaily stability
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: APOE ε4 allele presence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Actigraphy-estimated sleep variables at 7 days post-ICU discharge
Number of subjects: 150
Study: 32717315

Group type: EXPERIMENTAL
Intervention: Micra leadless pacemaker
Number of subjects: 104
Study: 32717365

Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (VCE) in patients with DA
Number of subjects: 201

Group type: COMPARATOR
Intervention: Video capsule endoscopy (VCE) in control patients (obscure GI bleeding or iron deficiency anemia)
Number of subjects: 201
Study: 32717408

Group type: EXPERIMENTAL
Intervention: Prognostic gene expression signature
Number of subjects: 483
Study: 32718212

Group type: EXPERIMENTAL
Intervention: Implantoplasty (IP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No implantoplasty (control)
Number of subjects: 41
Study: 32718257

Group type: EXPERIMENTAL
Intervention: Family history of AF (368 patients, 21.4%)
Number of subjects: 1722

Group type: COMPARATOR
Intervention: No family history of AF
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: Patients with ≥2 relatives affected by AF (3.5%)
Number of subjects: 1722
Study: 32718289

Group type: EXPERIMENTAL
Intervention: Treat to Target (T2T) strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 32718560

Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 0
Study: 32718723

Group type: EXPERIMENTAL
Intervention: Electronic risk calculator for BIMS developed and validated using logistic regression with bootstrapping.
Number of subjects: 16079

Group type: EXPERIMENTAL
Intervention: Simplified index based on preoperative haemoglobin <120 g L.
Number of subjects: 16079
Study: 32718876

Group type: EXPERIMENTAL
Intervention: Flow cytometry-based method for quantifying viable lymphocyte immunophenotypes
Number of subjects: 0
Study: 32718906

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W) for ≤24 months or until confirmed progression or unacceptable toxicity
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W)
Number of subjects: 44
Study: 32718926

Group type: EXPERIMENTAL
Intervention: CNSD users (n=100)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Z-hypnotics
Number of subjects: 246
Study: 32718997

Group type: EXPERIMENTAL
Intervention: Alpelisib (350 mg) combined with tamoxifen plus goserelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg) combined with tamoxifen plus goserelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buparlisib
Number of subjects: 0
Study: 32719074

Group type: EXPERIMENTAL
Intervention: 0/1-hour hs-cTnT algorithm
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Rule-out group
Number of subjects: 1711
Study: 32719417

Group type: EXPERIMENTAL
Intervention: Oral digoxin 0.5 mg
Number of subjects: 40
Study: 32719455

Group type: EXPERIMENTAL
Intervention: pyrotinib with capecitabine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: androgen receptor inhibitor with CDK4/6 inhibitor
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: anti PD-1 with nab-paclitaxel
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: PARP inhibitor included
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: anti-VEGFR included
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: mTOR inhibitor with nab-paclitaxel
Number of subjects: 69
Study: 32719636

Group type: EXPERIMENTAL
Intervention: 7-month professional development/education module for preschool staff
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1200
Study: 32719915

Group type: EXPERIMENTAL
Intervention: In vivo imaging of mitochondrial membrane potential (ΔΨ)
Number of subjects: 13
Study: 32719964

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 504
Study: 32720004

Group type: EXPERIMENTAL
Intervention: Engagement in traditional practices
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Substance use (alcohol, marijuana, methamphetamine)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Commercialized tobacco use
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cognitive functioning
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Spiritual connectedness
Number of subjects: 63
Study: 32720012

Group type: EXPERIMENTAL
Intervention: Patients with acute surgical condition and concomitant COVID-19 (Group A)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Patients with severe COVID-19 developing acute abdominal pathologies (Group B)
Number of subjects: 215
Study: 32720016

Group type: EXPERIMENTAL
Intervention: OSAHS patients (mild, moderate, severe)
Number of subjects: 242

Group type: COMPARATOR
Intervention: non-OSAHS patients
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Severity of OSAHS
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CIMT, carotid plaque, blood flow velocity, and blood lipid
Number of subjects: 242
Study: 32720404

Group type: EXPERIMENTAL
Intervention: Wide QRS (LBBB, RBBB, non-specific IVCD, QRS 110-129 ms)
Number of subjects: 11861

Group type: EXPERIMENTAL
Intervention: New-onset LBBB
Number of subjects: 11861

Group type: EXPERIMENTAL
Intervention: QRS widening ≥130 ms
Number of subjects: 11861
Study: 32720457

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 172
Study: 32720900

Group type: EXPERIMENTAL
Intervention: eHealth Literacy Scale (eHEALS)
Number of subjects: 1695
Study: 32720911

Group type: EXPERIMENTAL
Intervention: TECH+PHONE group
Number of subjects: 433

Group type: COMPARATOR
Intervention: SC group
Number of subjects: 433

Group type: COMPARATOR
Intervention: TECH group
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: SAM (20 items)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Convergent validity using motivation for weight loss scale
Number of subjects: 433
Study: 32721016

Group type: EXPERIMENTAL
Intervention: UX023-CL201, UX023-CL205, UX023-CL301 (interventional trials)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: UX023-CL002 (observational, retrospective chart review)
Number of subjects: 228
Study: 32721110

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF)
Number of subjects: 30
Study: 32721404

Group type: EXPERIMENTAL
Intervention: Bedside Swallowing Evaluation (BSE)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: BSE-based decision tree algorithm
Number of subjects: 213

Group type: COMPARATOR
Intervention: Flexible Endoscopic Evaluation of Swallowing (FEES)
Number of subjects: 213
Study: 32721422

Group type: EXPERIMENTAL
Intervention: NIBB APBI using a dose of 34 Gy in 10 fractions delivered daily or twice a day.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NIBB APBI
Number of subjects: 40
Study: 32721510

Group type: EXPERIMENTAL
Intervention: High haemoglobin group
Number of subjects: 518

Group type: COMPARATOR
Intervention: Low haemoglobin group
Number of subjects: 518
Study: 32721547

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS) scales
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Defense and Veterans Pain Rating Scale (DVPRS)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Legacy scales
Number of subjects: 121
Study: 32721891

Group type: EXPERIMENTAL
Intervention: Surgical separation of parasitic twins
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 4
Study: 32721954

Group type: EXPERIMENTAL
Intervention: Narsoplimab, a monoclonal antibody against MASP-2, dosage and duration not specified.
Number of subjects: 0
Study: 32721955

Group type: EXPERIMENTAL
Intervention: Multi-biomarker strategy using 12 top ranked plasma proteins
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Multi-biomarker strategy in patients with normal CgA concentrations
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 135
Study: 32722686

Group type: EXPERIMENTAL
Intervention: Parenthood (mothers with varying parity)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Parenthood (parents of one child)
Number of subjects: 235
Study: 32722801

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study: 32723298

Group type: EXPERIMENTAL
Intervention: Four square step test
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 89
Study: 32723341

Group type: EXPERIMENTAL
Intervention: ePRMs assessment integrated with EMR
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Edmonton symptom assessment scale
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Distress Thermometer
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Adapted patient reported experience tool
Number of subjects: 600
Study: 32723388

Group type: EXPERIMENTAL
Intervention: Twitter engagement through @ELFStudy
Number of subjects: 952
Study: 32723525

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 42
Study: 32723590

Group type: EXPERIMENTAL
Intervention: Diabetes-specific dementia risk score (DSDRS)
Number of subjects: 2241
Study: 32723735

Group type: EXPERIMENTAL
Intervention: Patients with the highest probabilities for progression
Number of subjects: 297

Group type: COMPARATOR
Intervention: Patients with lower probabilities for progression
Number of subjects: 297
Study: 32723990

Group type: EXPERIMENTAL
Intervention: Asthma medication adherence assessment through patient interviews using four questions from the Malaysian Medication Adherence Scale.
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Assessment of asthma control using the Global Initiative for Asthma (GINA) Assessment of Symptom Control.
Number of subjects: 1011
Study: 32724669

Group type: EXPERIMENTAL
Intervention: OCT imaging
Number of subjects: 3631

Group type: EXPERIMENTAL
Intervention: Well-monitored patients (≥8 OCT examinations)
Number of subjects: 3631

Group type: EXPERIMENTAL
Intervention: Combination of OCT and fluorescein angiography imaging
Number of subjects: 3631
Study: 32725443

Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy (RT) with simultaneous boost to the intraprostatic lesion
Number of subjects: 65
Study: 32725444

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg at extended dosing intervals (>4 weeks)
Number of subjects: 109